ELTX insider transaction filings
Elicio Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-02. Screen ELTX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 11 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| ADAMS JULIAN — Director | 1 | — | — | 1 |
| Ashe Carol Gail — Director | 1 | — | — | 1 |
| Chudnovsky Yekaterina — Director, 10% owner | 1 | — | — | 1 |
| Connelly Robert — CEO, President and Director, Director | 1 | — | — | 1 |
| DeMuth Peter — Chief Scientific Officer | 1 | — | — | 1 |
| Haqq Christopher — See Remarks | 1 | — | — | 1 |
| Nissenson Allen — Director | 1 | — | — | 1 |
| RUFFOLO ROBERT R — Director | 1 | — | — | 1 |
| Shah Preetam — See Remarks | 1 | — | — | 1 |
| Venkatesan Jay — Director | 1 | — | — | 1 |
+1 more insider in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Elicio Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Venkatesan Jay — Director | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | WILSON KAREN J — Director | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | RUFFOLO ROBERT R — Director | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | Nissenson Allen — Director | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | Chudnovsky Yekaterina — Director, 10% owner | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | Ashe Carol Gail — Director | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | ADAMS JULIAN — Director | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | DeMuth Peter — Chief Scientific Officer | Grant/award (A): 52,832 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | Connelly Robert — CEO, President and Director, Director | Grant/award (A): 186,944 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | Shah Preetam — See Remarks | Grant/award (A): 60,833 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4 | Haqq Christopher — See Remarks | Grant/award (A): 64,643 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Connelly Robert — CEO, President and Director, Director | Grant/award (A): 73,600 @ $0 · Grant/award (A): 147,200 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Shah Preetam — See Remarks | Grant/award (A): 24,000 @ $0 · Grant/award (A): 47,900 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | DeMuth Peter — Chief Scientific Officer | Grant/award (A): 20,800 @ $0 · Grant/award (A): 41,600 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Haqq Christopher — See Remarks | Grant/award (A): 25,400 @ $0 · Grant/award (A): 50,900 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | DeMuth Peter — Chief Scientific Officer | Option exercise (M): 362 @ $4.41 · Option exercise (M): 362 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Chudnovsky Yekaterina — Director, 10% owner GKCC, LLC — 10% owner | Grant/award (A): 103,225 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Ashe Carol Gail — Director | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Chudnovsky Yekaterina — Director, 10% owner | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Nissenson Allen — Director | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Venkatesan Jay — Director | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | WILSON KAREN J — Director | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | ADAMS JULIAN — Director | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | RUFFOLO ROBERT R — Director | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Shah Preetam — See Remarks | Grant/award (A): 191,624 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Chudnovsky Yekaterina — Director, 10% owner GKCC, LLC — 10% owner | Conversion (C): 3,500,573 @ $5.81 · Conversion (C): 3,442,341 (derivative) @ $5.81 | EDGAR |
| 2025-02-04 | 4 | DeMuth Peter — Chief Scientific Officer | Grant/award (A): 44,400 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Haqq Christopher — See Remarks | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Connelly Robert — CEO, President and Director, Director | Grant/award (A): 121,600 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4/A | Venkatesan Jay — Director | Purchase (P): 50,000 (derivative) @ $0 · Purchase (P): 50,000 (derivative) @ $4.99 | EDGAR |
| 2024-12-18 | 4 | DeMuth Peter — Chief Scientific Officer | Option exercise (M): 381 @ $4.41 · Option exercise (M): 381 (derivative) @ $0 | EDGAR |
| 2024-11-29 | 4 | Venkatesan Jay — Director | Option exercise/expiry (X): 50,000 @ $0.01 · Option exercise/expiry (X): 50,000 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Ashe Carol Gail — Director | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Chudnovsky Yekaterina — Director, 10% owner | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Nissenson Allen — Director | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Venkatesan Jay — Director | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | WILSON KAREN J — Director | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | ADAMS JULIAN — Director | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | RUFFOLO ROBERT R — Director | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Connelly Robert — CEO, President and Director, Director | Grant/award (A): 91,600 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | DeMuth Peter — Chief Scientific Officer | Grant/award (A): 29,800 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Haqq Christopher — See Remarks | Grant/award (A): 28,200 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Chudnovsky Yekaterina — Director, 10% owner GKCC, LLC — 10% owner | Purchase (P): 3,442,341 (derivative) @ $5.81 | EDGAR |
| 2024-07-02 | 4 | Chudnovsky Yekaterina — Director, 10% owner GKCC, LLC — 10% owner | Purchase (P): 1,600,000 (derivative) @ $0 · Purchase (P): 1,600,000 (derivative) @ $4.99 | EDGAR |
| 2024-07-02 | 4 | Venkatesan Jay — Director | Purchase (P): 50,000 (derivative) @ $0 · Purchase (P): 50,000 (derivative) @ $4.99 · Purchase (P): 50,000 (derivative) @ $0 · Purchase (P): 50,000 (derivative) @ $4.99 · Purchase (P): 50,000 (derivative) @ $0 · Purchase (P): 50,000 (derivative) @ $4.99 · +2 more | EDGAR |
| 2024-03-20 | 4 | Chudnovsky Yekaterina — Director, 10% owner GKCC, LLC — 10% owner | Purchase (P): 1,032,702 (derivative) @ $5.81 | EDGAR |
| 2024-02-05 | 4 | Piekos Brian — Chief Financial Officer | Grant/award (A): 43,225 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Connelly Robert — CEO, President and Director, Director | Grant/award (A): 225,137 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Haqq Christopher — See Remarks | Grant/award (A): 28,200 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | DeMuth Peter — Chief Scientific Officer | Grant/award (A): 29,800 (derivative) @ $0 · Grant/award (A): 342 (derivative) @ $0 | EDGAR |
Recent 8-K events — Elicio Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | ? 8.01 — Other Events | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-06-17 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-15 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ELTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →